Who Will Be Accountable for AI Harms? Lessons From Valproate.

Why It Matters

Without decisive accountability, AI products can cause systemic failures, eroding trust and exposing companies to costly liability and regulatory backlash.

Key Takeaways

• Developer liability essential for trustworthy AI deployment
• Overreliance on AI risks deskilling and mis‑skilling of professionals
• Valproate case shows decades‑long lag in risk mitigation
• Legal action often triggers regulatory response, not proactive safety
• Shared accountability without clear enforcement stalls meaningful reform

Pulse Analysis

AI’s rapid integration into healthcare, finance, and consumer products has outpaced the development of robust governance structures. While industry voices call for shared responsibility among developers, regulators, and users, the article stresses that only a clear, enforceable liability regime for developers can anchor safety standards. Pre‑market evaluations must verify algorithmic accuracy and bias mitigation, while post‑market monitoring should track real‑world performance, ensuring that implementers remain vigilant and that any emergent harms are swiftly addressed.

The pharmaceutical experience with valproate illustrates how delayed risk management can become a cautionary tale for AI. Early studies in the 1980s linked prenatal exposure to birth defects and neurodevelopmental disorders, yet comprehensive risk‑management plans were not instituted until 2015, spurred by a mother’s lawsuit. This lag mirrors scenarios where AI systems are deployed without thorough testing, only prompting regulatory scrutiny after high‑profile failures. The parallel underscores the need for proactive safety protocols rather than reactive legal triggers.

Policymakers and industry leaders must therefore craft a layered accountability model that combines developer liability with mandatory safety audits, transparent reporting, and compensation mechanisms for affected parties. Such a framework would incentivize early risk identification, reduce the burden of post‑incident litigation, and restore confidence among investors and consumers. By learning from valproate’s protracted oversight, the AI sector can avoid repeating history and foster sustainable, trustworthy innovation.